478 results
Search Results
2. A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia
3. Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations
4. Assessment of the absorption, metabolism and excretion of [14C]pasireotide in healthy volunteers using accelerator mass spectrometry
5. The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases
6. Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer
7. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors
8. Pharmacokinetics and metabolism of SL-01, a prodrug of gemcitabine, in rats
9. Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors
10. Pharmacokinetics and tissue distribution of larotaxel in rats: comparison of larotaxel-loaded microsphere with larotaxel-solution
11. A phase I pharmacokinetic study of PM00104 (Zalypsis®) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors
12. A mathematical model for the administration of temozolomide: comparative analysis of conventional and metronomic chemotherapy regimens
13. A phase I study of tasisulam sodium using an albumin-tailored dose in Japanese patients with advanced solid tumors
14. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years
15. A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors
16. Phase I dose-escalation study of oral vinflunine administered once daily for 6 weeks every 8 weeks in patients with advanced/metastatic solid tumours
17. Pharmacokinetics of docetaxel in gastric cancer patients with malignant ascites
18. Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine
19. Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study
20. In vitro cytotoxicity, pharmacokinetics, tissue distribution, and metabolism of small-molecule protein kinase D inhibitors, kb-NB142-70 and kb-NB165-09, in mice bearing human cancer xenografts
21. Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration
22. Comparison of pharmacokinetics and safety profiles of two capecitabine tablet formulations in patients with colon, colorectal or breast cancer
23. Effects of famotidine or an antacid preparation on the pharmacokinetics of nilotinib in healthy volunteers
24. Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects
25. Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors
26. A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors
27. Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment
28. Phase I study of nelfinavir in liposarcoma
29. Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity
30. A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors
31. A phase 1 study of vinflunine in combination with trastuzumab for the treatment for HER2-positive metastatic breast cancer
32. Single-dose pharmacokinetic and toxicity analysis of pyrrole–imidazole polyamides in mice
33. Pharmacokinetics of sepantronium bromide (YM155), a small-molecule suppressor of survivin, in Japanese patients with advanced solid tumors: dose proportionality and influence of renal impairment
34. Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia
35. Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer
36. Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors
37. Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers
38. Single- and multiple-dose pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in Chinese men with advanced solid tumors
39. Comparison of a homologous series of benzonaphthyridine anti-cancer agents in mice: divergence between tumour and plasma pharmacokinetics
40. A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors
41. The minimal impact of food on the pharmacokinetics of ridaforolimus
42. Modeling and simulation approaches to evaluate pharmacokinetic sampling contamination from central venous catheters in pediatric pharmacokinetic studies of actinomycin-D: a report from the children’s oncology group
43. Preclinical pharmacology of novel indolecarboxamide ML-970, an investigative anticancer agent
44. 9-Amino acridine pharmacokinetics, brain distribution, and in vitro/in vivo efficacy against malignant glioma
45. Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men
46. The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients
47. The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus
48. Pharmacokinetics and tissue and tumor exposure of CP-31398, a p53-stabilizing agent, in rats
49. Exposure–response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection
50. Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children’s Oncology Group study
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.